FDA will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to discuss seven peptides for potential inclusion on the 503A bulks list. An additional five peptides will be ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Peptides are all anyone wants ...

Every investor has heard this quote at least once in their career: “Compound interest is the eighth wonder of the world. He who understands it earns it. He who doesn’t pays it," is a quote often ...

You’ve probably seen compounding making headlines recently, and not for the right reasons. From so-called “personalized” GLP-1s flooding the market to telehealth startups touting hormone “rebalancing” ...

In March, Pharmaceutical Executive reported on Eli Lilly’s efforts to push back against the availability of compounded GLP-1 ...

Study on compounded GLP-1s uncovers use of additives and questionable sterility practices, revealing legally ‘murky’ area.

Hikma Pharmaceuticals (LON:HIK) said it has made an “encouraging start” to 2026 and reiterated its full-year group guidance, citing performance across all three of its businesses and continued robust ...

Outraged over a 2012 fungal meningitis outbreak traced back to Framingham, Massachusetts-based drug compounder New England Compounding Center (NECC) that left sixty-four people dead and more than 700 ...

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

Please provide your email address to receive an email when new articles are posted on . As of the end of October, 28 deaths resulting from the use of poorly prepared compounded medications by a ...